Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Rapid oral desensitisation to ethambutol, rifampicin and isoniazid Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009
Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006
The impact of ethambutol optic toxicity on treatment of MDR TB Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
High-dose rifampicin and rifapentine in tuberculosis treatment Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015
Efficacy of intravenous isoniazid, rifampin and ethambutol administration in patients with failed treatment of tuberculosis and malabsorption syndrome Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
In vitro susceptibility to rifampin and ethambutol and treatment outcome in MAC lung disease Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM) Year: 2018
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment Source: Eur Respir J 2015; 45: 554-557 Year: 2015
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Two months isoniazid, rifampin and pirazinamid for latent tuberculosis infection Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Monoresistance to rifampicin – a problem for treatment results? Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010